Want to see PFSA full AI Analyst Report?
PFSA Stock Chart & Stats
$5.00
-$0.50(-29.24%)
At close: 4:00 PM EDT
$5.00
-$0.50(-29.24%)
Day’s Range― - ―
52-Week Range$1.58 - $3,001.24
Previous Close$1.18
Volume6.10M
Average Volume (3M)3.69M
Market Cap
$1.20M
Enterprise Value$13.96
Total Cash (Recent Filing)$719.00K
Total Debt (Recent Filing)$14.00M
Price to Earnings (P/E)―
Beta1.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding605,647
10 Day Avg. Volume10,067,838
30 Day Avg. Volume3,690,810
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-9.87
Price to Sales (P/S)0.00
P/FCF Ratio-16.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Tissue-integrated Biosensor PlatformProfusa’s tissue-integrated sensor addresses continuous physiological monitoring through an implantable device paired with an external reader. If technically validated and commercialized, this platform could support multiple health and performance applications and create a differentiated product foundation.
Potential Diagnostics Revenue ScaleThe proposed G3 acquisition could materially change Profusa’s scale by adding commercial diagnostics operations, national CLIA-certified laboratories, and provider-based recurring revenue. However, the option remains conditional on financing, approvals, debt arrangements, and continued Nasdaq listing.
Debt-to-equity RestructuringExchanging approximately $6.14 million of secured notes into preferred equity reduces the immediate secured-debt burden and may improve capital-structure flexibility. Moving a creditor position toward equity can also ease repayment pressure, although it concentrates ownership and may dilute common shareholders.
Bears Say
No Commercial Revenue And Widening LossesThe absence of recorded revenue indicates that Profusa has not yet reached commercial scale, while widening losses and negative gross profit show substantial expense intensity without operating support. This limits evidence of product-market traction and makes near-term profitability dependent on execution or financing.
Persistent Cash Burn And External Funding NeedSustained operating and free-cash-flow deficits mean Profusa is consuming capital rather than internally funding development. Continued reliance on external financing can constrain strategic choices, increase dilution or interest costs, and leave the business exposed if new capital is unavailable.
Fragile, Creditor-protected Capital StructureNegative equity and debt that greatly exceeds the small asset base indicate limited balance-sheet resilience. Recent secured convertible notes pledge substantially all assets and include mandatory prepayment and high default-interest provisions, potentially restricting financial flexibility and increasing shareholder risk.
Profusa News
PFSA FAQ
What was Profusa’s price range in the past 12 months?
Profusa lowest stock price was $1.58 and its highest was $3001.24 in the past 12 months.
What is Profusa’s market cap?
Profusa’s market cap is $1.20M.
When is Profusa’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Profusa’s earnings last quarter?
Currently, no data Available
Is Profusa overvalued?
According to Wall Street analysts Profusa’s price is currently Overvalued.
Does Profusa pay dividends?
Profusa does not currently pay dividends.
What is Profusa’s EPS estimate?
Profusa’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Profusa have?
Profusa has 605,647 shares outstanding.
What happened to Profusa’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Profusa?
Currently, no hedge funds are holding shares in PFSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Profusa
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Technical Analysis
Ownership Overview
37.04% Insiders
0.97% Mutual Funds
― Other Institutional Investors
61.99% Public Companies and
Individual Investors